CRISPR Therapeutics Files 8-K
Ticker: CRSP · Form: 8-K · Filed: Oct 15, 2025 · CIK: 1674416
Sentiment: neutral
Topics: 8-K, routine-filing, disclosure
Related Tickers: CRSP
TL;DR
CRISPR Therapeutics filed a routine 8-K on 10/15/25, no major news.
AI Summary
CRISPR Therapeutics AG filed an 8-K on October 15, 2025, reporting other events and financial statements. The filing does not contain specific details on new events, financial figures, or material agreements, but serves as a routine disclosure.
Why It Matters
This 8-K filing by CRISPR Therapeutics AG is a standard disclosure, indicating no immediate material events or changes to report as of October 15, 2025.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' with no specific material events disclosed, suggesting no immediate new risks.
Key Players & Entities
- CRISPR Therapeutics AG (company) — Registrant
- October 15, 2025 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing by CRISPR Therapeutics AG is to report 'Other Events' and 'Financial Statements and Exhibits' as of October 15, 2025.
Does this filing announce any new material events or agreements?
This filing does not specify any new material events, agreements, or executive changes. It appears to be a routine disclosure.
What is the company's principal executive office address?
The principal executive offices of CRISPR Therapeutics AG are located at Baarerstrasse 14, 6300 Zug, Switzerland.
What is the SIC code for CRISPR Therapeutics AG?
The Standard Industrial Classification (SIC) code for CRISPR Therapeutics AG is 2836, which corresponds to 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
When is CRISPR Therapeutics AG's fiscal year end?
CRISPR Therapeutics AG's fiscal year ends on December 31.
Filing Stats: 641 words · 3 min read · ~2 pages · Grade level 11.8 · Accepted 2025-10-15 16:18:42
Key Financial Figures
- $600,000,000 — ng an aggregate offering price of up to $600,000,000 (the "Offering"). The Common Shares for
Filing Documents
- crsp-20251015.htm (8-K) — 56KB
- crsp-ex5_1.htm (EX-5.1) — 98KB
- img33470342_0.jpg (GRAPHIC) — 5KB
- img33470342_1.jpg (GRAPHIC) — 3KB
- 0001193125-25-240282.txt ( ) — 279KB
- crsp-20251015.xsd (EX-101.SCH) — 25KB
- crsp-20251015_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. As previously reported, on August 30, 2019, CRISPR Therapeutics AG (the "Company") entered into an Open Market Sale Agreement TM (the "Agreement") with Jefferies LLC ("Jefferies"), under which the Company may offer and sell, from time to time at its sole discretion through Jefferies, as its sales agent, its common shares, nominal value of CHF 0.03 per share (the "Common Shares"). On October 15, 2025, the Company filed a prospectus supplement with the U.S. Securities and Exchange Commission (the "SEC") to offer and sell from time to time at its sole discretion through Jefferies, as its sales agent, additional Common Shares having an aggregate offering price of up to $600,000,000 (the "Offering"). The Common Shares for the Offering will be offered and sold pursuant to the Company's previously filed automatically effective shelf registration statement on Form S-3ASR (File No. 333-281262) filed by the Company with the SEC on August 5, 2024. The legal opinion of Walder Wyss AG relating to the legality of the issuance and sale of the Common Shares in the Offering is attached as Exhibit 5.1 to this Current Report on Form 8-K. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 5.1* Opinion of Walder Wyss AG 23.1* Consent of Walder Wyss (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CRISPR Therapeutics AG Date: October 15, 2025 By: /s/ Samarth Kulkarni Samarth Kulkarni, Ph.D. Chief Executive Officer